Medtronic plc Annual Report - How They Did This Year

I’ve put together this guide to help you understand Medtronic’s performance over the past year. Instead of digging through hundreds of pages of dense financial filings, I’ve broken down the important details here to help you decide if this company fits your portfolio.

1. What does this company do?

Medtronic is a global leader in healthcare technology. They design, make, and sell medical devices to hospitals and doctors worldwide. The company operates in three primary areas: Cardiovascular, Neuroscience, and Medical Surgical. They earn money by selling high-tech equipment—like heart devices and surgical robots—and providing ongoing support for these tools.

2. A Major Structural Change: The Diabetes Spin-off

The biggest news this year is that Medtronic is slimming down. In March 2026, they finished spinning off their Diabetes business into an independent company called MiniMed Group, Inc.

• What this means for you: Medtronic is now more focused on its core heart, brain, and surgical tech. Keep in mind that older financial reports include the Diabetes unit, so they won't perfectly match future reports.

3. Financial performance (Fiscal Year Ended April 24, 2026)

Medtronic remains a massive, stable company.

• Revenue and Profit: For the fiscal year ending April 24, 2026, the company brought in $32.4 billion in sales. Profit was $3.6 billion, which reflects costs from the Diabetes spin-off.
• Market Value: As of October 2025, the company was worth approximately $120.1 billion.
• Shareholder Returns: Medtronic is a "dividend aristocrat," having raised its annual dividend for 48 years in a row. They continue to return cash to shareholders through these regular payouts and stock buybacks.
• Debt: The company carries significant long-term debt, with notes due between 2027 and 2053. This debt helps fund their heavy investment in research and development, which totaled $2.7 billion this year.

4. Major wins and challenges

• Wins: Their diversification is a major strength. Operating across many specialties helps them offset market ups and downs. For example, growth in surgical robotics helped stabilize performance when other product lines slowed down.
• Challenges: They are navigating high interest rates. Because they carry significant debt, higher rates increase interest costs, which can squeeze profit margins. They also face regulatory hurdles from agencies like the FDA, which can delay product launches and slow down the return on their research investments.

5. Future outlook: The "Smart" Pivot

Medtronic is shifting from just selling hardware to building a tech-enabled ecosystem. Their strategy focuses on three areas:

1. Innovation: Prioritizing high-growth markets like robotic surgery and AI-integrated diagnostics.
2. Better Outcomes: Using clinical data to prove to hospitals and insurers that their therapies save money.
3. AI and Automation: Using data and AI to tailor therapies in real-time. By offering remote monitoring, they make their products "stickier." Once a hospital uses Medtronic’s data system, it is difficult and expensive for them to switch to a competitor.

6. Key risks

Beyond competition and regulation, the company highlighted these concerns:

• Cybersecurity: Expanding remote monitoring increases their exposure to data breaches.
• Global Instability: With operations in over 150 countries, they are sensitive to geopolitical conflicts, currency changes, and trade policies that can disrupt logistics.
• Supply Chain: They rely on specialized parts from third-party suppliers. Any interruption in manufacturing or shipping can hurt their ability to fulfill hospital orders.

7. Market trends

The global population is aging. As people get older, demand for chronic disease management—especially in heart, spine, and surgical care—is growing. This provides a natural boost for Medtronic, as their core business is tied to essential medical procedures that remain necessary regardless of the economy.

Decision Tip: When considering Medtronic, weigh their long history of dividend growth and market leadership against the potential impact of high interest rates on their debt-heavy balance sheet. If you believe in the long-term shift toward AI-integrated surgical robotics, their current "smart" pivot strategy may be the most important factor to watch.

Disclaimer: I’m a friend, not a financial advisor. Always do your own research before buying stocks.